Meeder Asset Management Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.4% during the third quarter, according to its most recent filing with the SEC. The fund owned 71,610 shares of the medical research company’s stock after buying an additional 6,159 shares during the quarter. Amgen accounts for approximately 1.5% of Meeder Asset Management Inc.’s portfolio, making the stock its 16th largest holding. Meeder Asset Management Inc.’s holdings in Amgen were worth $30,184,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Quest 10 Wealth Builders Inc. raised its stake in Amgen by 220.0% in the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 55 shares during the period. Wellington Altus USA Inc. increased its stake in shares of Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after purchasing an additional 34 shares in the last quarter. Nvwm LLC increased its stake in shares of Amgen by 412.5% in the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after purchasing an additional 66 shares in the last quarter. PFS Partners LLC raised its position in shares of Amgen by 95.5% in the third quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 42 shares during the period. Finally, TOWER TRUST & INVESTMENT Co bought a new stake in shares of Amgen in the third quarter valued at approximately $38,000. Institutional investors own 76.50% of the company’s stock.
Analyst Ratings Changes
Several research firms recently commented on AMGN. Barclays raised their price objective on shares of Amgen from $400.00 to $430.00 and gave the stock an “equal weight” rating in a report on Monday. Wells Fargo & Company increased their target price on Amgen from $430.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 4th. Cantor Fitzgerald raised their price target on Amgen from $440.00 to $465.00 and gave the stock a “neutral” rating in a report on Wednesday, November 4th. Royal Bank Of Canada raised their price target on Amgen from $430.00 to $470.00 and gave the stock an “outperform” rating in a report on Wednesday, November 4th. Finally, Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, October 18th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $425.69.
Get Our Latest Stock Analysis on AMGN
Amgen Stock Down 0.9%
AMGN opened at $439.77 on Thursday. The firm has a market capitalization of $237.87 billion, a P/E ratio of 25.33, a price-to-earnings-growth ratio of 3.19 and a beta of 0.43. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The company has a fifty day moving average price of $428.15 and a 200-day moving average price of $382.85. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.79 by $0.66. The business had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. Amgen’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the previous year, the business posted $5.64 earnings per share. Equities research analysts expect that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.
Amgen Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s dividend payout ratio (DPR) is presently 58.47%.
About Amgen
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
See Also
- Five stocks we like better than Amgen
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
